When was Baoji Pharmaceutical founded?

Baoji Pharmaceutical was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Baoji Pharmaceutical located?

Baoji Pharmaceutical is headquartered in Baoshan, China.

Is Baoji Pharmaceutical a funded company?

Baoji Pharmaceutical is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Aug 25, 2022.

When was the latest funding round of Baoji Pharmaceutical?

Baoji Pharmaceutical's latest funding was a $***** Series B round on Aug 25, 2022, with participation from 4 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does Baoji Pharmaceutical rank among its competitors?

Baoji Pharmaceutical ranks 4th amongst 32 active competitors, of which 10 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Virometix, which secured $15M in Nov, 2025.

Who are the top competitors of Baoji Pharmaceutical?

Baoji Pharmaceutical's top competitors include CStone Pharma, Ensoma and Enlaza. Among them, Virometix secured the most recent funding round in November, 2025.

Baoji Pharmaceutical - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics for multiple diseases. It offers recombinant protein drugs and antibody drugs based on mammalian cells and microbial expression systems for cancer, assisted reproduction, and anemia

Website: www.baopharma.com
Email ID: *****@baopharma.com
Phone Number: +86 **********

Key Metrics

Founded Year

2019

Location

Baoshan, China

Stage

Public

Total Funding

$100M in 1 round

Latest Funding Round

Series B, Aug 25, 2022, $*****

Investors

Oriental Fortune Capital & 3 more

Ranked

4^th among 32 active competitors

Similar Companies

CStone Pharma & 31 more

Exit Details

Public

View Baoji Pharmaceutical's full profile

Baoji Pharmaceutical got listed on Dec 10, 2025.

Click here to take a look at Baoji Pharmaceutical's IPO in detail

Baoji Pharmaceutical has raised a total funding of $100M over 1 round. Its latest funding round was a Series B round on Aug 25, 2022 for $*****. 4 investors participated in its latest round. Baoji Pharmaceutical has 4 institutional investors.

Here is the list of recent funding rounds of Baoji Pharmaceutical:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2022	9031629	Series B	7451182	8010846	1292597	5923668

Access funding benchmarks and valuations. Sign up today!

View details of Baoji Pharmaceutical's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Baoji Pharmaceutical include CStone Pharma, Ensoma and Enlaza. Here is the list of Top 10 competitors of Baoji Pharmaceutical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CStone Pharma 2016, Shanghai (China), Public	Developing and licensing novel drugs for diseases including cancer and autoimmune diseases	$410M	GIC, 6 Dimensions Capital & 14 others	59/100
2nd	Ensoma 2019, Boston (United States), Series B	Developer of in vivo hematopoietic stem cell engineering for genomic medicine	$205M	5AM Ventures, Arix Bioscience & 18 others	58/100
3rd	Enlaza 2020, La Jolla (United States), Series A	Developer of protein therapeutics for the treatment of cancer and other serious diseases	$176M	Avalon Ventures, J P Morgan & 9 others	57/100
4th	Baoji Pharmaceutical 2019, Baoshan (China), Public	Developer of therapeutics for multiple diseases	$100M	Haitong Securities, Shenzhen Sunrise Investment Management ... & 2 others	54/100
5th	Virometix 2009, Zurich (Switzerland), Series C	Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial and viral) and cancer	$29.4M	Venture Kick	50/100
6th	GlobeImmune 1995, Louisville (United States), Public	Developing Tarmogen (vaccine) product candidates to treat cancer and infectious diseases.	$132M	Celgene, Wexford Capital & 19 others	49/100
7th	Topas Therapeutics 2016, Hamburg (Germany), Series B	Developer of nanoparticle-based therapeutics for immunology disorders	$68.5M	Epidarex Capital, Boehringer Ingelheim Venture Fund ... & 7 others	44/100
8th	Luzhu Biotech 2001, Tongzhou (China), Public	Developer of human vaccines and biological drugs for multiple diseases	$72.9M	CCB International, Tigermed & 6 others	42/100
9th	IMMvention 2015, Sunnyvale (United States), Series A	Developer of anti-inflammatory therapies for neurodegenerative and cardiometabolic diseases	$8.9M	Carolina Research Ventures Fund, Osage University Partners ... & 3 others	40/100
10th	Prologue Medicines 2023, Belmont (United States), Series C	Developer of therapeutic potential of viral proteins to create transformative medicines	$50M	Flagship Pioneering	38/100